UPDATE 1-GSK diabetes drug set for European approval

Fri Jan 24, 2014 8:25am EST

LONDON Jan 24 (Reuters) - GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan.

Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk, as well as Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca .

A positive recommendation for a drug by the European Medicines Agency (EMA) is generally followed by a marketing authorisation by the European Commission. GlaxoSmithKline (GSK) said a final decision was anticipated later this quarter.

Albiglutide has been approved for patients for whom the widely-used metformin is considered inappropriate, and as an add-on therapy when other glucose-lowering products do not provide adequate glycaemic control, the EMA said.

Carlo Russo, GSK's senior vice president for R&D, said the recommendation was a major milestone towards offering people with uncontrolled type 2 diabetes a new option to help manage their condition.

The drug met its main goal in five studies reported last year, but it did not demonstrate it was equally as good as pioglitazone, an existing diabetes treatment.

Industry analysts therefore have said it may struggle against competitors, and new drugs in development, such as Eli Lilly's dulaglutide.

The consensus forecast for albiglutide currently points to modest annual sales of about $400 million by 2018, according to a Thomson Reuters Pharma survey of six analysts.

Last year regulators in the United States pushed back an approval decision on the drug until April 15.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
raroman wrote:
This week two long awaited new human clinical trial results in which the effect of Transmax Resveratrol as a preventative and adjunct treatment for Type 2 Diabetes were released.  What distinguishes these recent human trials is the larger number of subjects tested, the rigid selection criteria used, and the examination of Resveratrol’s effects on body weight, blood pressure, cholesterol, and overall health effects in addition to Resveratrol’s benefits to the obese and diabetic patients.  In these human clinical trials Transmax was shown to have important beneficial action with respect to both prevention of Metabolic Syndrome from evolving into Type 2 Diabetes. Specifically, transmax lowered blood glucose and blood pressure, improved insulin sensitivity, and caused a weight loss in obese patients. Evidence was also presented which confirms that Transmax Resveratrol could attenuate many of the pathologies associated with severe Diabetes, including loss of vision, circulatory problems, and chronic inflammation.

Jan 24, 2014 5:32pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.